^
    22d
    Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=61, Completed, invoX Pharma Limited | Active, not recruiting --> Completed | N=146 --> 61 | Trial completion date: Dec 2024 --> Jul 2024 | Trial primary completion date: Dec 2024 --> Jul 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Tecentriq (atezolizumab) • SB 11285
    4ms
    Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=146, Active, not recruiting, invoX Pharma Limited | Recruiting --> Active, not recruiting | Trial completion date: Mar 2027 --> Dec 2024 | Trial primary completion date: Mar 2027 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Tecentriq (atezolizumab) • SB 11285
    9ms
    Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=146, Recruiting, invoX Pharma Limited | Phase classification: P1a/1b --> P1 | Trial completion date: Oct 2025 --> Mar 2027 | Trial primary completion date: Oct 2023 --> Mar 2027
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Tecentriq (atezolizumab) • SB 11285
    over1year
    Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=146, Recruiting, F-star Therapeutics, Inc. | N=110 --> 146 | Trial completion date: May 2022 --> Oct 2025 | Trial primary completion date: Dec 2021 --> Oct 2023
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Tecentriq (atezolizumab) • SB 11285
    over4years
    [VIRTUAL] A phase I/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumours (ESMO 2020)
    Funding: Spring Bank Pharmaceuticals. Clinical trial identification: NCT04096638.
    Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    Opdivo (nivolumab) • SB 11285
    over4years
    [VIRTUAL] A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors. (ASCO 2020)
    The trial is being conducted at multiple sites in the U.S . Research Funding: Spring Bank Pharmaceuticals, Inc.
    Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    Opdivo (nivolumab) • SB 11285